Physician profile
Daniel D Alfaro
NPI 1982719290
$15,016.40
in general payments reported to CMS, 2019-2025
45 companies · $1,116 in 2025
The $1,116 reported for 2025 was more than what 80% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,094 · 2020: $1,029 · 2021: $1,403 · 2022: $6,832 · 2023: $1,662 · 2024: $879 · 2025: $1,116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,088 · Travel and Lodging: $449 · Entertainment: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,087.92 |
| Travel and Lodging | $449.44 |
| Entertainment | $120.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $7,045.91 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $1,078.95 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $944.55 | 2019-2023 | Vabysmo |
| Alimera Sciences, INC. | $617.05 | 2019-2024 | Iluvien, Yutiq |
| Abbvie INC. | $520.44 | 2022-2025 | Ozurdex, Qulipta, Ubrelvy |
| Abbott Laboratories | $449.44 | 2023 | Aveir |
| Allergan, INC. | $430.11 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $425.91 | 2019-2021 | |
| Eyepoint US, INC. | $327.61 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $293.13 | 2019-2021 | |
| Astellas Pharma US INC | $272.82 | 2023-2025 | Izervay |
| Biogen, INC. | $252.69 | 2022-2023 | |
| Harrow Eye, LLC | $249.72 | 2023-2025 | Iheezo |
| Coherus Oncology, INC. | $230.21 | 2023 | |
| Apellis Pharmaceuticals, INC. | $191.75 | 2024-2025 | Syfovre |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $187.22 | 2019-2021 | |
| Neurotech Pharmaceuticals, INC. | $171.50 | 2025 | |
| Mallinckrodt Hospital Products INC. | $169.18 | 2022 | |
| Ocular Therapeutix, INC. | $155.37 | 2019-2024 | Dextenza |
| Optos, INC. | $140.42 | 2021-2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Alcon Vision LLC | $124.45 | 2025 | Constellation |
| Dutch Ophthalmic, USA | $116.59 | 2020-2024 | Eva, Combined Machine, Tissueblue |
| Genentech, INC. | $112.00 | 2021 | |
| Aerie Pharmaceuticals, INC. | $111.52 | 2019 | |
| Carl Zeiss Meditec, INC. | $84.58 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $70.05 | 2022-2023 | Vyzulta, Lotemax Sm, Miebo |
| Omeros Corporation | $49.29 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $48.54 | 2024-2025 | Purified Cortrophin Gel, Iluvien |
| Notal Vision, INC. | $32.55 | 2024 | Foresee Home |
| Sun Pharmaceutical Industries INC. | $22.24 | 2019 | |
| Rayner Intraocular Lenses Limited | $20.44 | 2025 | Rayone Aspheric, Rayone Spheric, Rayner Cataract Set 1 |
| Eyevance Pharmaceuticals LLC | $20.43 | 2022 | |
| Travere Therapeutics, INC. | $18.56 | 2019-2020 | |
| Horizon Therapeutics Plc | $17.60 | 2021 | |
| Amgen INC. | $13.58 | 2024 | Tepezza |
10 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$27,083.33 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Alfaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.